

Nivolumab CheckMate025

### PRELIMINARY SCORE

**CURATIVE**



**NON-CURATIVE**



### ADJUSTMENTS

**Quality of life**



Improved QoL

**Serious and disabling adverse effects**



Less serious and disabling adverse events observed

**Other adjustments**



Nivolumab CheckMate025

### SCORE

**CURATIVE**



Overall Survival / Disease-Free Survival / Pathological Complete Response

**NON-CURATIVE**




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

**INFORMATION**

Tumour type: Genitourinary Cancers  
 Therapeutic Indication: As monotherapy for the treatment of advanced renal cell carcinoma after prior therapy in adults  
 Experimental Arm: Nivolumab  
 Control Arm: Everolimus



